Company Overview
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 by Charles Homcy and headquartered in South San Francisco, California, that uses human genetics as its primary drug discovery engine. The company's approach begins with population-scale genetic data to identify individuals who are naturally protected from diseases like chronic kidney disease (CKD), obesity, and cardiovascular disorders — then designs small-molecule drugs that mimic the protective genetic effect in the broader patient population. This genetics-first model is designed to increase the probability of clinical success by targeting validated mechanisms with demonstrated human proof of concept before any clinical trial begins.
Business Model & Competitive Advantage
Maze's lead programs include MZE829 and MZE782, both targeting chronic kidney disease — one of the largest unmet needs in medicine, affecting roughly 37 million Americans and associated with high cardiovascular mortality and rapid progression to dialysis. The company is also exploring precision approaches for obesity and metabolic diseases, where genetic stratification could identify patient subgroups most likely to respond. Maze has raised over $290M in total funding from investors including GV (Google Ventures), Casdin Capital, Foresite Capital, and ARCH Venture Partners — a high-pedigree investor base reflecting confidence in its genetic discovery platform.
Competitive Landscape 2025–2026
Maze Therapeutics differentiates from traditional biotech drug discovery through the scale and rigor of its genetic analysis infrastructure. The company's platform integrates large-scale human genetic datasets (biobanks, GWAS studies, whole-exome sequencing) with functional genomics and medicinal chemistry to move from genetic signal to drug candidate with greater speed and confidence. This positions Maze alongside other genetics-driven biotechs like Goldfinch Bio and Verve Therapeutics, but with a broader multi-disease focus anchored to renal and metabolic health.
Key Differentiators
Emerging Innovator
Maze Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Maze Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Maze Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Maze Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Maze Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →